Sermorelin vs tesamorelin: which is better for you?

Last updated 2026-07-24

What are sermorelin and tesamorelin, and how are they different?

Both drugs are synthetic versions of growth-hormone-releasing hormone (GHRH), the signal your hypothalamus sends to your pituitary gland to make it release its own growth hormone. Neither one is growth hormone. That's the first thing people get wrong when they compare these to HGH itself. Sermorelin is a 29-amino-acid fragment that mimics the active end of natural GHRH. It was originally sold in the US under the brand name Geref, approved by the FDA for diagnosing and treating growth hormone deficiency in children and for GH-deficiency testing in adults ^[1]. The manufacturer discontinued Geref for business reasons, not because of a safety recall. That distinction matters, because it means sermorelin's molecule has an actual FDA approval history behind it, even though today it's only available through compounding pharmacies as an unapproved compounded product. Tesamorelin is a modified, stabilized GHRH analog sold under the brand name Egrifta (and the reformulated Egrifta SV). It's still an FDA-approved drug today, specifically for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy ^[2]. It is not approved for anti-aging use, athletic performance, or general fat loss in people without HIV. So right away, the comparison isn't really apples to apples. Sermorelin is a legacy molecule with no current FDA-approved product on the market. Tesamorelin is an active, approved drug for one specific condition. Whether one is 'better' depends entirely on what problem you're trying to solve, which is the question this whole article is built around.

Which is better, sermorelin or tesamorelin, for growth hormone deficiency?

For classic adult growth hormone deficiency, neither drug is the first-line answer anymore, but sermorelin has the more direct regulatory history for it. Geref (sermorelin) was FDA-approved specifically as a diagnostic and treatment agent for GH deficiency, including in children with growth failure due to inadequate GHRH secretion ^[1]. Tesamorelin has never carried an indication for general GH deficiency. Its single FDA approval is narrow: reducing visceral fat in HIV patients with lipodystrophy ^[2]. Using it for GH deficiency would be off-label, and there's much less clinical trial data supporting that use than there is for the approved indication. In practice, most endocrinologists treating confirmed adult GH deficiency today reach for recombinant human growth hormone (HGH) itself, not a GHRH analog. It gives more direct and titratable dosing. Endocrine Society guidelines describe stimulation testing followed by recombinant GH replacement as the standard approach for confirmed adult GH deficiency ^[3]. Sermorelin's modern use has shifted almost entirely to compounding pharmacies prescribing it off-label for adults with low-normal GH or IGF-1 levels who don't meet the strict criteria for HGH therapy. If you want the details on what a real dosing schedule looks like, the sermorelin dosage chart breaks down typical protocols.

Which is better for losing belly fat, sermorelin or tesamorelin?

Tesamorelin has the actual clinical trial data for this; sermorelin does not. In phase 3 trials in HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue significantly more than placebo over 26 weeks, which is part of why the FDA approved it for that specific population ^[2][4]. The pooled phase 3 studies (Falutz et al., published in the Journal of Clinical Endocrinology & Metabolism) reported a treatment difference in visceral adipose tissue of roughly 15-18% relative to placebo, depending on which trial and endpoint you look at ^[4]. That data does not generalize to a healthy 45-year-old wanting to lose belly fat. Tesamorelin has not been shown in rigorous trials to reduce visceral fat in people without HIV lipodystrophy, and using it that way is off-label with a much thinner evidence base. Sermorelin's fat-loss evidence is even sparser. There are small, older studies looking at sermorelin's effects on GH and IGF-1 levels in adults, but nothing resembling the tesamorelin lipodystrophy trials in size or rigor. Clinics that market sermorelin for 'fat loss' or 'body recomposition' are extrapolating from its mechanism (more GH release should support fat metabolism) rather than pointing to trials that measured actual fat loss outcomes in that population. Honest bottom line: if visceral fat reduction backed by real trial data is what you want, tesamorelin's evidence is stronger, but only within the HIV lipodystrophy population it was studied in. Outside that population, you're relying on extrapolation either way.

How do the costs of sermorelin and tesamorelin compare?

Tesamorelin (brand Egrifta SV) is expensive. As a branded, patent-protected specialty drug, list prices commonly run over $3,000 to $4,000 per month before insurance or manufacturer assistance programs, and insurance coverage is often restricted to the approved HIV lipodystrophy indication ^[2]. Outside that indication, most insurers won't cover it, and compounded tesamorelin has become more common as a lower-cost, non-FDA-approved alternative, though its quality and dosing consistency depend entirely on the compounding pharmacy. Sermorelin is markedly cheaper. Because it's compounded rather than sold as a branded product, typical monthly costs for a compounded sermorelin prescription generally fall somewhere in the $150 to $350 range depending on dose and pharmacy, though prices vary a lot by region and provider. There's no branded sermorelin product currently on the US market to compare list prices against, since Geref was discontinued. Neither drug is typically covered by insurance when used off-label for anti-aging, body composition, or general wellness purposes. If cost is the deciding factor and you don't have HIV-associated lipodystrophy, sermorelin is going to be the far less expensive option in nearly every case.

How do sermorelin and tesamorelin dosing schedules compare?

Which has better safety data, sermorelin or tesamorelin?

Tesamorelin has the more rigorous, modern safety dataset, because it went through full FDA phase 3 trials for its approved indication. Common side effects reported in those trials included injection site reactions, joint pain (arthralgia), swelling (edema), and muscle pain, along with increases in IGF-1 levels that require periodic monitoring ^[2][4]. The FDA label also carries warnings about the theoretical risk of tumor growth stimulation, since GH and IGF-1 can promote the growth of some existing malignancies, which is why tesamorelin isn't recommended in patients with active malignancy. Sermorelin's safety history is older but longer. As Geref, it was studied and approved by the FDA in the 1990s, and its side effect profile from that era included injection site redness, flushing, headache, and dizziness ^[1]. What sermorelin lacks is a modern trial base for the way it's actually being used today, mostly off-label, longer-term, in adults seeking general wellness or body composition benefits rather than diagnosed GH deficiency. That gap matters. Nobody has good long-term data on what happens after years of nightly compounded sermorelin use in healthy adults, because that population wasn't who the original trials studied. For a fuller rundown of what's known and what's genuinely uncertain, see sermorelin long-term side effects. Both drugs share the same class-wide theoretical concerns: they raise IGF-1, and elevated IGF-1 over long periods is a legitimate thing to monitor with bloodwork, not something to wave off.

Is sermorelin or tesamorelin more like HGH, and does that matter?

Neither one is HGH, and that's the central thing to understand before comparing them to actual growth hormone therapy. Both sermorelin and tesamorelin work upstream: they stimulate your own pituitary gland to make and release more of your own GH, a mechanism described in reviews of GH secretagogues ^[6]. Injectable recombinant HGH (somatropin) skips that step entirely and puts finished growth hormone directly into your bloodstream. That upstream mechanism is sermorelin and tesamorelin's biggest theoretical safety advantage over HGH: because they rely on your pituitary's own feedback loops, they generally can't push GH release past what your body is physiologically capable of producing, which may lower the risk of the more severe overdose-type side effects seen with direct HGH administration. It's also their biggest limitation. If your pituitary gland is severely damaged or nonfunctional, no amount of GHRH analog will make it produce more GH, and direct HGH replacement becomes the only option. For otherwise healthy adults with GH levels in the low-normal range, sermorelin is often marketed as a gentler, more 'natural' alternative to HGH. That framing isn't wrong mechanistically, but it's also not backed by trials showing it delivers the same measurable outcomes (body composition change, strength, energy) that direct HGH therapy has shown in deficient populations. If you're trying to decide between sermorelin and HGH itself, the honest answer is that sermorelin is the gentler, cheaper, less-studied option, and HGH is the stronger, better-documented, and more expensive one with a tighter regulatory approval path. For a full breakdown, sermorelin covers the mechanism and evidence base in more depth.

Can you switch between sermorelin and tesamorelin, or combine them?

There's no clinical reason to combine sermorelin and tesamorelin, since they act on the same receptor (the GHRH receptor on pituitary somatotroph cells) through a similar mechanism. Using both together wouldn't be expected to add benefit and would mainly add cost and injection burden. Switching between them is more common in practice. Someone using compounded sermorelin for general wellness purposes who develops HIV-associated lipodystrophy, for example, would be a candidate for tesamorelin specifically because that's what it's approved and trial-tested for. Conversely, someone on tesamorelin for an approved indication wouldn't typically switch to sermorelin unless cost became prohibitive and a prescriber judged the off-label alternative reasonable for that patient. Any switch should go through the prescriber who ordered bloodwork (IGF-1, GH levels) in the first place, not through a patient self-adjusting based on price alone.

Where can you get sermorelin or tesamorelin legally?

Tesamorelin as Egrifta SV is available through retail and specialty pharmacies with a prescription, since it's an FDA-approved drug ^[2]. Compounded tesamorelin also exists through compounding pharmacies, which is not FDA-approved but is legal when compounded appropriately under a valid prescription and in line with federal compounding rules under Section 503A of the Food, Drug, and Cosmetic Act ^[7]. Sermorelin has no FDA-approved branded product currently on the market (Geref was discontinued), so all sermorelin sold today is compounded. That means quality control, purity, and dosing accuracy depend heavily on which compounding pharmacy fills the prescription. Reputable telehealth and clinic models pair a licensed prescriber's evaluation (bloodwork, medical history) with a named, accountable compounding pharmacy rather than shipping product with no medical oversight at all. Sermorelin Co works this way: a provider reviews your labs and history before anything ships, and prescriptions are filled through a named compounding pharmacy partner rather than an anonymous supplier. If you're comparing options, sermorelin reviews is a reasonable next stop, and sermorelin peptide near me covers what to look for in a local or telehealth provider. Buying either peptide from research-chemical websites with no prescription, no medical review, and no pharmacy accountability is a real risk. Products sold that way aren't verified for sterility, dose accuracy, or even correct identity, and you have no prescriber checking whether the drug is appropriate for you at all.

So, which is actually better, sermorelin or tesamorelin?

It depends entirely on what you're treating, and anyone who gives you a flat answer without asking that first is skipping a step. If you have HIV-associated lipodystrophy and visceral fat reduction is the goal, tesamorelin is the better-evidenced choice, full stop. It has FDA approval, phase 3 trial data, and a specific indication that matches your situation ^[2][4]. If you're an adult with low-normal GH or IGF-1 levels looking for a lower-cost, lower-dose way to support your body's own GH production, without a diagnosed condition that tesamorelin is approved for, sermorelin is the more practical and affordable option, with the caveat that modern trial data on its off-label use is thin. If you're actually growth hormone deficient in the clinical sense, confirmed by stimulation testing, neither peptide is likely to be your prescriber's first choice. Direct HGH replacement therapy has the strongest evidence base for that specific diagnosis ^[3]. The honest, unglamorous answer: match the drug to the diagnosis, not the drug to the marketing. A prescriber who orders bloodwork before prescribing either one is doing it right.

Frequently asked questions

Is tesamorelin stronger than sermorelin?

In terms of GH release per injection, tesamorelin is generally considered a more potent, stabilized GHRH analog, and its approved dose (1-2 mg) delivers more measurable IGF-1 increase in trials than typical sermorelin doses (0.2-0.3 mg). 'Stronger' isn't the same as 'better for you,' though; it depends on what condition you're treating ^[2][3].

Why was sermorelin (Geref) discontinued?

The manufacturer discontinued Geref for business and manufacturing reasons, not because of a safety recall or FDA-ordered withdrawal. The FDA approval itself was never revoked for safety; the branded product simply stopped being manufactured, which is why sermorelin today exists only as a compounded, non-FDA-approved product ^[1].

Does insurance cover sermorelin or tesamorelin?

Tesamorelin (Egrifta SV) can be covered by insurance when prescribed for its approved indication, HIV-associated lipodystrophy, though prior authorization is common. Sermorelin, sold only as a compounded product, is almost never covered by insurance regardless of the reason it's prescribed. Off-label use of either drug is rarely covered.

Can tesamorelin be used for anti-aging like sermorelin sometimes is?

Tesamorelin is not FDA-approved for anti-aging use; its only approval is for reducing visceral fat in HIV-associated lipodystrophy. Some clinics prescribe it off-label for body composition goals, but this isn't backed by the same trial data as its approved use, and it costs far more than sermorelin for a similar off-label rationale.

Which peptide has more clinical trial data, sermorelin or tesamorelin?

Tesamorelin has the more current and rigorous trial data, including phase 3 trials that led to FDA approval for HIV-associated lipodystrophy. Sermorelin's clinical trial data is older, mostly from its original 1990s approval as Geref for GH deficiency, with little modern research on its current off-label uses.

Is sermorelin cheaper than tesamorelin?

Yes, significantly. Compounded sermorelin typically costs roughly $150-350 per month, while branded tesamorelin (Egrifta SV) commonly runs $3,000-4,000+ per month before insurance or assistance programs. Compounded tesamorelin exists as a lower-cost alternative but still tends to cost more than sermorelin.

Do sermorelin and tesamorelin have the same side effects?

They share a similar side effect class: injection site reactions, headache, and elevated IGF-1 requiring monitoring. Tesamorelin's FDA trials also documented joint pain and swelling (edema) more specifically. Both carry a theoretical, class-wide caution around stimulating growth in existing tumors, since GH and IGF-1 support cell growth.

Can I use sermorelin instead of HGH?

Sermorelin works differently than HGH: it stimulates your pituitary to make more of your own GH, rather than supplying GH directly. For confirmed GH deficiency, HGH itself has stronger evidence. For adults without a deficiency diagnosis, sermorelin is a gentler, cheaper, less-studied option, not a proven equivalent to HGH therapy.

Which is better for HIV-related fat loss, sermorelin or tesamorelin?

Tesamorelin, without question. It's the only one of the two with FDA approval and phase 3 trial data specifically for reducing excess abdominal fat in HIV-associated lipodystrophy, showing a meaningful reduction in visceral adipose tissue versus placebo over 26 weeks in trials.

How long does it take to see results from sermorelin or tesamorelin?

Tesamorelin's phase 3 trials measured visceral fat changes at 26 weeks. Sermorelin's off-label protocols generally suggest checking IGF-1 levels and subjective changes around 3 to 6 months, though rigorous modern timelines for off-label sermorelin use aren't well established in trials.

Is compounded tesamorelin as good as branded Egrifta SV?

Compounded tesamorelin isn't FDA-approved, so it hasn't gone through the same manufacturing and quality checks as Egrifta SV. It can be a reasonable lower-cost option through a legitimate compounding pharmacy with a valid prescription, but purity and dosing consistency depend entirely on that specific pharmacy's standards.

Do I need bloodwork before starting sermorelin or tesamorelin?

Yes. A responsible prescriber checks IGF-1 and often GH levels before starting either peptide, both to confirm the treatment is appropriate and to have a baseline for monitoring. Ongoing labs during treatment help catch IGF-1 levels rising too high, which is a real, monitorable risk with both drugs.

Sources

1. FDA Drug Approvals and Databases, Geref (sermorelin acetate) NDA 019667 approval history: Sermorelin was FDA-approved under the brand name Geref for growth hormone deficiency diagnosis and treatment, later discontinued for business reasons
2. FDA, Egrifta SV (tesamorelin for injection) prescribing information, NDA 209039: Tesamorelin is FDA-approved specifically for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, with associated side effects and monitoring requirements
3. Falutz J, et al. 'Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials.' J Clin Endocrinol Metab. 2010, PMID 19965919: Pooled phase 3 trials found tesamorelin significantly reduced visceral adipose tissue relative to placebo over 26 weeks in HIV-associated lipodystrophy
4. FDA, Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a), pharmacy compounding: Compounded drugs, including tesamorelin and sermorelin, are legal when compounded appropriately under a valid prescription and applicable federal compounding rules
5. ClinicalTrials.gov, 'Safety and Efficacy of Tesamorelin in HIV-Infected Patients With Excess Abdominal Fat', NCT00252529: A registered phase 3 trial evaluated tesamorelin's effect on visceral adipose tissue in HIV-associated lipodystrophy over a 26-week treatment period
6. Sigalos JT, Pastuszak AW. 'The Safety and Efficacy of Growth Hormone Secretagogues.' Sex Med Rev. 2018, PMID 28527742: GHRH analogs like sermorelin stimulate the pituitary's own GH release through feedback-regulated mechanisms rather than supplying GH directly
7. Molitch ME, et al. 'Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline.' J Clin Endocrinol Metab. 2011, PMID 21296991: Clinical guidelines describe stimulation testing and recombinant human growth hormone as the standard approach for confirmed adult GH deficiency
8. MedlinePlus (National Library of Medicine), Growth hormone deficiency: Growth hormone deficiency in adults and children is diagnosed through stimulation testing and monitored using GH and IGF-1 blood levels